The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 03, 2019

Filed:

Dec. 29, 2017
Applicant:

Northwestern University, Evanston, IL (US);

Inventors:

Chad A. Mirkin, Wilmette, IL (US);

Caroline H. Ko, Chicago, IL (US);

David A. Giljohann, Chicago, IL (US);

Janina Luciano, Champaign, IL (US);

Samuel A. Jensen, Bloomington, MN (US);

Alexander Stegh, Chicago, IL (US);

Assignee:

NORTHWESTERN UNIVERITY, Evanston, IL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); A61K 47/69 (2017.01); A61K 49/18 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 47/6923 (2017.08); A61K 47/6929 (2017.08); A61K 49/1851 (2013.01); C12N 15/113 (2013.01); C12N 2310/14 (2013.01); C12N 2320/32 (2013.01); C12N 2320/35 (2013.01);
Abstract

Polyvalent nanoconjugates address the critical challenges in therapeutic use. The single-entity, targeted therapeutic is able to cross the blood-brain barrier (BBB) and is thus effective in the treatment of central nervous system (CNS) disorders. Further, despite the tremendously high cellular uptake of nanoconjugates, they exhibit no toxicity in the cell types tested thus far. This property is critical for therapeutic agent delivery applications for reducing off-target effects.


Find Patent Forward Citations

Loading…